<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02438631</url>
  </required_header>
  <id_info>
    <org_study_id>PIANO</org_study_id>
    <nct_id>NCT02438631</nct_id>
  </id_info>
  <brief_title>Placental Passage and Disposition of Drugs: A Physiology-based Approach</brief_title>
  <acronym>PIANO</acronym>
  <official_title>Placental Passage and Disposition of Drugs: A Physiology-based Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>PENTA Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Top sector Life Sciences &amp; Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to integrate the outcomes in physiology-based pharmacokinetic (PBPK)&#xD;
      models to put the generated data into context with medical conditions that require maternal&#xD;
      or fetal drug therapy (e.g. HIV). These models will be validated with available 'real-life'&#xD;
      maternal and fetal PK data, such as data from the PANNA network.&#xD;
&#xD;
      PBPK models of drug therapy during pregnancy will provide a powerful tool to 1.) assist in&#xD;
      designing rational dosing adjustments, 2.) prevent intervention-based research in pregnant&#xD;
      women in the future, and 3.) guide future development of new molecular entities (e.g.&#xD;
      preventing heavy investment in drugs with high predicted fetal exposure and potentially toxic&#xD;
      effects in utero).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>placental transfer</measure>
    <time_frame>at delivery</time_frame>
    <description>1.) An ex-vivo placenta perfusion model will be used to estimate placental passage of drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>histological profiling</measure>
    <time_frame>at delivery</time_frame>
    <description>Histological and protein profiling experiments will be conducted to investigate factors that may influence the placental passage and disposition of drugs (e.g. the abundance, localization and inter-individual variation of expression of enzymes and transporters).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>in vitro experiments</measure>
    <time_frame>at delivery</time_frame>
    <description>Furthermore, in vitro experiments will be conducted to estimate the pharmacodynamic effects of drugs on the placental barrier function itself (e.g. whether exposure to drugs can induce/reduce the expression of enzymes and transporters, as has been reported for several organs, such as the liver, intestine and kidney).</description>
  </primary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Pregnancy</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Placental tissue is retained, limited sample. DNA will not be analysed.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  &gt;38 weeks pregnant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Retained placenta&#xD;
&#xD;
          -  HIV infected&#xD;
&#xD;
          -  Known hepatitis C infection&#xD;
&#xD;
          -  Multiple pregnancy&#xD;
&#xD;
          -  Congenital birth defects child&#xD;
&#xD;
          -  Sectio EXIT procedure&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J van Drongelen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>J van Drongelen</last_name>
    <email>joris.vandrongelen@Radboudumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radboud University Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joris M van Drongelen, MD PhD</last_name>
      <email>joris.vandrongelen@Radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>Joris van Drongelen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 6, 2015</study_first_submitted>
  <study_first_submitted_qc>May 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>placenta</keyword>
  <keyword>placental passage</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

